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Abstract
Recently, it was described that an HLA-A24 restricted peptide derived from the survivin splice
variant survivin-2B can be recognized by CD8(+) cytotoxic T-cells. The identification of an HLA-
A24 epitope is critical for survivin-based immunotherapy as HLA-24 is the most frequent HLA allele
in Asia. Consequently, this survivin-2B epitope is already a target in a clinical study in patients with
advanced or recurrent colorectal cancer expressing survivin. However, the splice variant survivin-
2B has been described to be pro-apoptotic, and is only expressed at low levels in most malignant
tissues. Furthermore, survivin-2B expression are significantly decreased in later tumor stages and
inversely correlated with tumor differentiation and invasion. Consequently, survivin is a more
general vaccination candidate than the splice variant survivin-2B. Here, we on the basis of
spontaneous immune responses in HLA-A24+ cancer patients describes that a HLA-A24-restricted
survivin epitopes does indeed exist. Consequently, this epitope is an attractive target for the
ongoing survivin-based peptide immunotherapy against cancer.
Background
The group of Sato recently attempted to identify a HLA-
A24-restricted epitope derived from the universal tumor
antigen survivin. Although unsuccessful, they reported
that an HLA-A24 restricted peptide (AYACNTSTL) derived
from the survivin splice variant survivin-2B can be recog-
nized by CD8(+) cytotoxic T-cells [1,2]. Subsequently, as
described in this journal this survivin-2B epitope is the
target in a phase I clinical study assessing the efficacy of
survivin-2B peptide vaccination in patients with advanced
or recurrent colorectal cancer expressing survivin [3].
As HLA-A24 is a very frequent allele expressed especially
in the Asian population a survivin-derived HLA-A24
restricted epitope would be highly interesting in peptide
based immunotherapy against cancer. Survivin is an
apoptotic inhibitor that is expressed at high levels in a
variety of malignancies. At present, four splicing variants
are known for survivin (Survivin, Survivin-2B, Survivin-
deltaEx3, Survivin-3B, and survivin-2α) [4-6]. Survivin is
over-expressed in almost all cancers including lung,
colon, breast, pancreas, stomach, liver, ovaries, and pros-
tate cancer, as well as melanoma, and hematopoetic
malignancies [7-9]. Data from a large analysis of human
transcripts revealed survivin as the fourth most highly
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normal tissue [10]. In contrast, the expression and func-
tion in human cancer of the splice variant the survivin-2B
is more indistinct. Thus, most studies describe survivin 2-
B as to be pro-apoptotic, and only to be expressed at low
levels in most malignant tissues [11]. Furthermore, sur-
vivin-2B expression are significantly decreased in later
tumor stages and inversely correlated with tumor differen-
tiation and invasion [4,11]. Likewise, Islam et al (2000)
reported that the expression of survivin-2B is predomi-
nant in some neuroblastoma with a good prognosis [12],
indicating a possible unfavourable role of survivin-2B in
cancer development [13]. In contrast, two recent papers
show that high expression of survivin-2B variant is corre-
lated with poor prognosis in cancer patients [14,15].
However, as survivin-2B is not expressed in many malig-
nancies, survivin is a more attractive candidate as a gen-
eral vaccination candidate than the splice variant survivin-
2B. In the present manuscript, we identified an HLA-A24




Peripheral blood lymphocytes (PBL) from HLA-A24 posi-
tive cancer patients were obtained from the University
Hospital in Herlev, Denmark. The PBL were isolated using
Lymphoprep separation and cryopreserved in FCS with
10% DMSO. Tissue typing was conducted at the Depart-
ment of Clinical Immunology, The State Hospital, Copen-
hagen, Denmark. Informed consent was obtained from
the patients before any of theses measures.
Interferon-γ and perforin ELISPOT
The interferon-γ and Perforin ELISPOT assays was used to
quantify peptide epitope-specific interferon-γ and per-
forin releasing effector cells, respectively as described pre-
viously [16,17]. Briefly, nitrocellulosebottomed 96-well
plates (MultiScreen MAIP N45; Millipore) were coated
with 7.5 μg/ml capture anti-human interferon-γ (Pf-80/
164, Mabtech, Sweden) or 30 μg/ml coating anti-human
perforin (Pf-80/164, Mabtech) in 100 μl sterile PBS per
well. The wells were washed and T2-A24 cells (a kind from
Yasuto Akiyama, Tokyo) and effector cells were added
with or without 10 μM peptide. In some assays isolated,
CD8 positive T-cells were used as effector cells using
CD8+ MACS microbeads (Miltenyi Biotec GmbH, Glad-
bach, Germany). After incubation (37°C/5%CO2)
medium was discarded and the wells were washed prior to
addition of the secondary detection Ab, anti-human bioti-
nylated interferon-γ (Mabtech) at 2 μg/ml in 75 μl PSB/
BSA per well or anti-human biotinylated perforin (Pf-344-
biotin, Mabtech) at 1 μg/ml in 100 μl PSB, respectively.
The plates were incubated at RT for 2 h, washed, and 100
μl of streptavidin-ALP (Mabtech) diluted 1:1000 in PBS,
was added to each well and the plates were incubated for
one hour at RT and the enzyme substrate NBT/BCIP (Inv-
itrogen Life Technologies) was added to each well. Upon
appearance of dark spots, the reaction was terminated by
washing with tap water. The spots were counted using the
ImmunoSpot Series 2.0 Analyzer (CTL Analyzers).
Results and discussion
Recently, a library of overlapping nonamers spanning the
length of the survivin protein was used to screen for pep-
tides capable of binding to different HLA alleles, includ-
ing HLA-A*2402 revealing that the peptides Sur20–28
(STFKNWPFL), Sur96–104 (LTLGEFLKL), Sur133–141
(RAIEQLAAM), Sur126–135 (ETAKKVRRAI) bind to
HLA-A24 [18]. These peptides were not included in the
study from Sato and colleagues. Subsequently, we scruti-
nized PBL from HLA-A24+ cancer patients of different ori-
gin by means of ELISPOT against these peptides as
described [19]. Indeed, strong and frequent CTL responses
were detected against Sur20–28 (STFKNWPFL) in cancer
patients of different origin as exemplified in figure 1a; an
HLA-A24+ renal cancer patient and an HLA-A24+ breast
cancer patient hosting strong spontaneous responses
against Sur20–28. We were able to detect a response
against Sur20–28 in three out of five examined cancer
patients (figure 1). The IFN-γ ELISPOT assay is one of the
most useful techniques for immunological monitoring of
HLA-A24 restricted T-cell responses against Sur20–28 in cancer pati n sFigure 1
HLA-A24 restricted T-cell responses against Sur20–
28 in cancer patients. A: Example of the ELISPOT plate 
performed with the strong responding renal cancer patient 
R1. B: Spontaneous T cell responses against Sur20–28 as 
measured by the ELISPOT assay. The average number of 
peptide specific IFNγ spots formed in response to Sur20–28 
among 3 × 105 in vitro stimulated PBL from four breast can-
cer patients (b1, b2, b3, b4), and 1 renal cancer patient (R1). 
Non-specific IFNγ spots are subtracted.Page 2 of 4
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measure of specific T cell activation. Previously, we and
others have identified CTL epitopes from e.g. survivin,
Bcl-2, tyrosinase, CEA, EpCam and Mage on the basis of
spontaneous T-cell responses in PBL from cancer patients
as presented here [19-25]. However, the IFN-γ ELISPOT
does not assess cell-mediated cytotoxicity directly as IFN-
γ secretion is not limited to only cytolytic CD8 T-cells
cells. Thus, although it has been shown that IFN-γ ELIS-
POT reactivity in most cases correlates with the capacity to
exhibit cytotoxic function, the formal prove for this
notion can only be obtained directly. Perforin is a key
mediator of target cell death and the perforin ELISPOT
assay was recently demonstrated to provide an estimation
of cytotoxic effector cell frequency [17]. To insure that the
ELISPOT positive cells were indeed CD8+ T-cells, we first
isolated CD8+ cells from PBL from eight cancer patients.
Subsequently, we analyzed these CD8+ cells both by IFN-
γ and perforin ELISPOT (figure 2). In six out of eight
patients we were able to detect not only an INF-γ response
but in addition a perforin response. Furthermore, the CD8
isolated cells from the eight patients were tested against
the irrelevant, HLA-A24-restricted epitope from HIV-1 gag
gp4167–75 (RYLKDQQLL) [26]. Data from these experi-
ments showed highly comparable results when testing
unpulsed T2-A24 cells vs. T2-A24 cells pulsed with HIV-1
gag gp4167–75, even after a 10 day stimulation of the CD8+
cells with the HIV-1 gag gp4167–75 peptide (data not
shown).
Thus, the Sur20–28 reacting cells in the patients PBL are
indeed cytotoxic, CD8+ effector cells. Consequently,
Sur20–28 is a very attractive target to be included in the
ongoing survivin-based peptide immunotherapy against
cancer.
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